Behavioural interventions to promote physical activity in a multiethnic population at high risk of diabetes: PROPELS three-arm RCT

Kamlesh Khunti,1,2* Simon Griffin,3,4 Alan Brennan,5 Helen Dallosso,2,6 Melanie Davies,1,7 Helen Eborall,8 Charlotte Edwardson,1,7 Laura Gray,9 Wendy Hardeman,10 Laura Heathcote,5 Joseph Henson,1,7 Katie Morton,11,12,13 Daniel Pollard,5 Stephen Sharp,3 Stephen Sutton,11 Jacqui Troughton6 and Thomas Yates1,7

1Diabetes Research Centre, College of Medicine, Biological Sciences and Psychology, University of Leicester, Leicester, UK
2NIHR Applied Research Collaboration, East Midlands, UK
3MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK
4Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
5School of Health and Related Research, University of Sheffield, Sheffield, UK
6Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UK
7NIHR Leicester Biomedical Research Centre, Leicester, UK
8Social Science Applied to Healthcare Improvement Research Group, Department of Health Sciences, University of Leicester, Leicester, UK
9Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, UK
10School of Health Sciences, University of East Anglia, Norwich, UK
11Behavioural Science Group, Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
12UKCRC Centre for Diet and Activity Research (CEDAR), MRC Epidemiology Unit, University of Cambridge, Cambridge, UK
13Innovia Technology Limited, Cambridge, UK

*Corresponding author kk22@leicester.ac.uk

Declared competing interests of authors: Kamlesh Khunti reports that he is a member of the National Institute for Health Research (NIHR) Health Technology Assessment Obesity Themed Call Board and Health Services and Delivery Research Funding Committee and that he has acted as an advisor to the National Institute for Health and Care Excellence (NICE). Melanie Davies has acted as an advisor to NICE. Daniel Pollard reports non-financial support from Novo Nordisk (Bagsværd, Denmark), Eli Lilly and Company Limited (Basingstoke, UK), Abbott (Maidenhead, UK), Diabetes Care, Sanofi-Aventis (Sanofi S.A., Paris, France) and Medtronic plc (Minneapolis, MN, USA) outside the submitted work.
Charlotte Edwardson received grants from NIHR during the conduct of the study (16/41/04, 15/190/42 and 14/231/20). Thomas Yates reports grants from NIHR Leicester Biomedical Research Unit during the conduct of the study. He was involved in contributing to an adapted version of the Walking Away intervention that is part the framework for the NHS Diabetes Prevention Programme, led by Ingeus (main contractor) and the Leicester Diabetes Centre, University Hospitals of Leicester (subcontractor).

Disclaimer: This report contains transcripts of interviews conducted in the course of the research and contains language that may offend some readers.
Scientific summary

Background

Type 2 diabetes is a leading cause of mortality and disability globally, accounting for significant health resource expenditure. The risk of diabetes can be reduced through increased physical activity. However, systematic reviews have identified limitations in the evidence as to whether or not previous diabetes prevention programmes have been successful at promoting physical activity behaviour change in the long term. There has been a particular lack of research assessing the effectiveness of physical activity interventions in minority ethnic groups, such as South Asian people, who are known to have a substantially elevated risk of developing type 2 diabetes.

Walking Away from Type 2 Diabetes (Walking Away) is a low-resource, group-based behavioural intervention designed to promote physical activity in those at risk of developing diabetes within primary care. Walking Away has already been commissioned into routine care pathways for the prevention of diabetes. This research sought to develop an integrated mobile health (mHealth) intervention to support the maintenance of behaviour change within Walking Away, and then test whether or not Walking Away promotes sustained increases in physical activity in a multiethnic population with and without the addition of the developed mHealth intervention.

Objectives

The preliminary objective was to develop a tailored mHealth intervention to provide follow-on support for participants referred to the Walking Away programme. The primary objective was then to investigate whether or not Walking Away can lead to sustained increases in physical activity after 4 years in an ethnically diverse population at high risk of type 2 diabetes, when delivered at two levels of ongoing follow-on maintenance support (with and without the developed mHealth intervention). This primary objective was supported by key secondary objectives, which were to compare the effectiveness of the tested interventions in white European and South Asian subgroups and to conduct a within-trial and long-term economic evaluation of each tested intervention.

Methods

Design

This was a three-arm, parallel-group, pragmatic, superiority randomised controlled trial. Treatment allocation was carried out using a web-based randomisation procedure provided by the Leicester Clinical Trials Unit, with equal allocation probabilities. Follow-up was conducted at 12 and 48 months. The primary outcome was objectively assessed ambulatory activity (steps per day) at 48 months. A total of at least 1308 participants was required to meet the sample size specifications.

Setting

Research was conducted at the Diabetes Research Centre, University of Leicester, and the MRC Epidemiology Unit, University of Cambridge. Participants were recruited from primary care or previous research cohorts and intervention delivery was conducted in community or health-care settings adjacent to participants’ general practices.
Participants
Participants were recruited from across Leicestershire and Cambridgeshire. The primary method of recruitment was directly through primary care using patient records: eligible participants were identified by their general practice and were sent an invitation letter and study information sheet by post. In Cambridge, participants who met the inclusion criteria were also recruited from existing population-level research studies. Participants were recruited if they had a blood glucose or glycated haemoglobin (HbA1c) value that indicated an elevated risk of type 2 diabetes (referred to as prediabetes) within the last 5 years. This was defined as fasting glucose of ≥ 5.5 mmol/l and < 7.0 mmol/l, 2-hour post-challenge glucose of ≥ 7.8 mmol/l and < 11.1 mmol/l, or HbA1c of ≥ 6.0% (42 mmol/mol) and < 6.5% (48 mmol/mol). Other inclusion criteria were being aged 40–74 years (25–74 years if South Asian) and having access to a mobile phone and being willing to use it as part of the study. Those who were unable to take part in walking activity, were pregnant or were unable to provide informed consent were excluded.

Interventions
Control
Participants were provided with an information leaflet targeting knowledge and perceptions of diabetes risk and the importance of physical activity in reducing risk.

Walking Away
A low-resource, 3-hour, group-based behavioural intervention aimed at targeting knowledge and perceptions of risk factors for type 2 diabetes, outcome expectations around the effectiveness of physical activity at managing those risk factors, physical activity self-efficacy, and the promotion of specific behaviour change techniques centred on the provision of pedometers to support goal-setting and self-monitoring. Walking Away was delivered by two trained educators to groups of up to 10 participants. Participants were also invited to attend 2.5-hour group-based refresher sessions at 12, 24 and 36 months.

Walking Away Plus
Participants were invited to attend the Walking Away programme and the annual refresher sessions as described above. They were also provided with additional follow-on support in the form of a tailored mHealth intervention that was developed specifically to be integrated with Walking Away. The mHealth intervention involved participants regularly texting their individual goals and their achieved daily steps to an automated system, which responded with tailored text messages targeting attitudes and beliefs, motivation, self-efficacy and continued use of behaviour change strategies. Participants were also given support in the form of telephone calls from trained educators at 1 week and 6 months following each annual group-based session.

Outcomes
The primary outcome was overall ambulatory activity (steps per day) at 48 months, measured using a waist-worn accelerometer (ActiGraph, ActiGraph, LLC, Pensacola, FL, USA), which also provided the time spent sedentary, along with time in light-intensity physical activity and moderate- to vigorous-intensity physical activity as secondary outcomes. In addition, a thigh-worn accelerometer (activPAL) provided the time spent sitting or lying, standing and walking. Physical activity was also measured by self-report (Recent Physical Activity Questionnaire). Intervention process measures relating to self-efficacy, illness perceptions and use of behaviour change strategies were captured by self-report. HbA1c and other standard clinical biochemical and anthropometric variables were also assessed.

Embedded qualitative substudies were also undertaken to provide qualitative insights. These used focus groups and telephone interviews and focused on the two novel aspects of the PROPELS intervention: its duration, and the provision of maintenance support through telephone calls and text messaging. Their aim was to further the understanding of influences on engagement with the
intervention; whether or not and how participants reported the intervention helping them to increase and/or maintain physical activity; and how participants and educators thought that the intervention might be improved.

The cost-effectiveness of the trial interventions was assessed by conducting two separate health economic analyses. The primary analysis was a model-based analysis using the School for Public Health Research Diabetes Prevention Model, which extrapolated trial outcomes over a lifetime horizon. The secondary analysis was an evaluation of the within-trial costs and outcomes, which assessed the costs and benefits of the interventions for the 4-year follow-up period of the trial, including costs per quality-adjusted life-year using utility scores derived from the EuroQol-5 Dimensions (EQ-5D). Both analyses took an NHS and Personal Social Services perspective. Costs for both analyses were valued in 2017/18 Great British pounds. Unit costs were obtained from nationally representative sources such as the NHS reference costs.

Results

We randomised 1366 individuals (median age 61 years, median body mass index 28.4 kg/m², median ambulatory activity 6638 steps per day, women 49%, black and minority ethnicity 28%), of whom 460 were allocated to control, 450 were allocated to Walking Away and 456 were allocated to Walking Away Plus. Approximately 80% attended the initial group-based behavioural intervention in both arms, with 78% of participants in the Walking Away Plus arm also registering for the text messaging service. Waist-worn accelerometer data were available for 1017 (74%) and 993 (73%) individuals at 12 and 48 months, respectively.

At 48 months, neither arm showed differences in objectively measured ambulatory activity compared with control [Walking Away Plus: 121 steps per day, 97.5% confidence interval (CI) –290 to 532 steps per day; Walking Away: 91 steps per day, 97.5% CI –282 to 463 steps per day]. This was consistent across ethnic groups.

Measures of self-reported physical activity (metabolic equivalent minutes per week, time in moderate to vigorous physical activity and time walking) were not significant at any time point, except for an increase in self-reported physical activity of 4.4 (97.5% CI 0.0 to 8.8) kJ/kg/day in the Walking Away Plus arm at 48 months.

At the intermediate, 12-month, follow-up, there were no differences in the Walking Away arm compared with the control arm in any of the objectively assessed or self-reported physical activity variables. However, participants in the Walking Away Plus arm were found to have increased their ambulatory activity by 547 (97.5% CI 211 to 882) steps per day compared with those in the control arm, and had increased their time spent walking by 8.5 (97.5% CI 3.3 to 13.7) minutes per day and in moderate to vigorous physical activity by 3.5 (97.5% CI 0.6 to 6.5) minutes per day compared with those in the control arm. In addition, at 12 months, participants in the Walking Away Plus arm had been 1.61 (97.5% CI 1.05 to 2.45) times more likely to achieve 150 minutes per week of unbouted moderate to vigorous physical activity than participants in the control arm.

In the Walking Away Plus arm, triglycerides were reduced at both 12 months (mean intervention effect –0.15 mmol/l, 97.5% CI –0.29 to –0.01 mmol/l) and 48 months (mean intervention effect –0.11 mmol/l, 97.5% CI –0.21 to 0.00 mmol/l) compared with control. The Walking Away arm lost around 1 kg in body weight at 12 and 48 months compared with control, with reductions observed in waist circumference and improvements seen in markers of liver function. Other lifestyle, anthropometric and biochemical variables were unchanged in both the Walking Away and the Walking Away Plus arms at 12 and 48 months compared with the control arm, as were symptoms of anxiety and depression.
Despite the lack of an intervention effect at 48 months, rates of self-reported engagement with the key behaviour change techniques were notably higher in the intervention arms than in the control arm. At 48 months, 64.2% of participants in the Walking Away Plus arm and 49.7% of participants in the Walking Away arm reported using a pedometer at least some of the time, compared with 19.7% in the control arm. Similarly, 40.9% and 30.6% in the Walking Away Plus and Walking Away arms, respectively, reported keeping an exercise log at least some of the time, compared with 11.1% in the control arm, and 78.8% and 73.0% in the Walking Away Plus and Walking Away arms, respectively, reported setting themselves exercise goals, compared with 64.0% in the control arm. However, participants in all arms reported high levels of self-efficacy in engaging on physical activity at baseline, and these levels remained high throughout the intervention.

The findings from the embedded qualitative study also suggested that participants actively engaged with the interventions and found the experience positive, with the tailored mHealth follow-on support reported as being helpful. However, a common theme was that major illnesses, injury or life events that had occurred during the 4-year trial period in this older population had caused relapse and discontinuation with the programme, after which it was hard to re-engage.

The real-world costs of delivering Walking Away and Walking Away Plus were estimated as £257 and £322 per person, respectively. The probabilistic lifetime costs of Walking Away and Walking Away Plus (£22,945 and £23,018, respectively) remained higher than those of standard care (£22,598). Lifetime cost-effectiveness modelling over a 30-year horizon suggested that standard care had the highest probability of being cost-effective below a threshold of £20,000 per QALY. It was further estimated that, to reach a threshold of £20,000 per QALY, the Walking Away Plus arm would have to be delivered at a maximum cost of £116 per person. However, there was a high level of uncertainty in these estimates, with the value-of-information analyses indicating that the total value to the UK of research to eliminate all uncertainty can be estimated at £279,559,484.

Conclusions

Despite continued engagement with behaviour change techniques, and modest but clinically meaningful changes in physical activity at 12 months, combining a group-based physical activity intervention designed for implementation in primary care with text messaging and telephone support did not result in sustained changes at 48 months.

Although the findings from the embedded qualitative studies suggested a positive impact on physical activity levels and understanding of diabetes risk, combining a group-based physical activity intervention designed for implementation in primary care with text messaging and telephone support may not be cost-effective over the trial period or over a lifetime.

The increased ownership and adoption of self-monitoring technologies in the wider population during the years PROPELS was running was a contextual influence on participants in all three study arms that should be given consideration. The characteristics of the participants at baseline should also be noted; the majority of the participants recruited were not confirmed to have HbA1c values within the prediabetes range at baseline, and > 50% achieved 150 minutes of moderate to vigorous physical activity, with high levels of physical activity self-efficacy reported at baseline in all arms. These findings may, therefore, be generalisable only to relatively healthy, active participants, and not necessarily to those referred to diabetes prevention programmes within primary care. Nevertheless, this study is consistent with the wider literature in both active adults and those with diagnosed type 2 diabetes, as very few studies have reported sustained increases in objectively assessed physical activity beyond 12 months.
The embedded qualitative research revealed several explanations for the poor sustainability of the physical activity increase found in the trial. Notably, factors related to ageing and associated health risks and conditions featured prominently, with falls, accidents or surgery – and the associated recovery – leading to long periods of reduced activity. This suggests that effectiveness may be enhanced by incorporating additional support designed to improve resilience to such life events that participants can call on in the event of a major health issue/illness.

Future research should, therefore, focus on identifying the intervention types, components and features that are most successful in helping maintain physical activity behaviour change over the long term and in diverse populations; evaluating the long-term effectiveness and cost-effectiveness of routinely delivered national diabetes prevention programmes; testing a stepped prevention programme of initial lifestyle intervention before offering pharmacological interventions (e.g. metformin) to those who do not adhere to or are unable to take up lifestyle interventions; illuminating the importance of risk status and risk communication to behaviour change; and exploring the importance of integrating rehabilitation from illness or injury as a core intervention component to sustain long-term physical activity behaviour change.

**Trial registration**

This trial is registered as ISRCTN83465245.

**Funding**

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment; Vol. 25, No. 77*. See the NIHR Journals Library website for further project information.
Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 4.014

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 09/162/02. The contractual start date was in November 2012. The draft report began editorial review in March 2020 and was accepted for publication in June 2021. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

Copyright © 2021 Khunti et al. This work was produced by Khunti et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HSDR, PGfAR, PHR journals) and Editor-in-Chief of HSDR, PGfAR, PHR journals

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Consultant in Public Health, Delta Public Health Consulting Ltd, UK

Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont  Senior Adviser, Wessex Institute, University of Southampton, UK

Dr Catriona McDaid  Reader in Trials, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, Child and Adolescent Mental Health, Palliative Care and Paediatrics Unit, Population Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk